Acute kidney injury (AKI) is estimated to occur in up to 60% of critically ill patients.[@bib1], [@bib2], [@bib3] Patients who experience AKI in the intensive care unit (ICU) have a mortality risk of 20% to 50% and patients with severe AKI requiring renal replacement therapy (AKI-RRT) have a mortality risk of 40% to 80%.[@bib2], [@bib4], [@bib5], [@bib6] Renal recovery (no longer requiring RRT) can occur in up to 50% of patients, but the probability of recovery is difficult to assess.[@bib7], [@bib8] The pathogenesis of AKI-RRT and mechanisms for recovery are incompletely understood.

Elevations in plasma uric acid levels (hyperuricemia) are common in patients with decreased kidney function from chronic kidney disease (CKD) and AKI. Multiple studies have found associations between higher uric acid levels and increased risk for the development of chronic systemic illnesses such as hypertension,[@bib9] cardiovascular disease,[@bib10], [@bib11] and CKD.[@bib12], [@bib13] Prior studies have demonstrated higher uric acid levels as a risk factor for the development of contrast-induced AKI[@bib14], [@bib15] and AKI after cardiac surgery.[@bib16], [@bib17], [@bib18], [@bib19] Few studies have investigated the potential role of uric acid in inciting or perpetuating AKI in critically ill patients. In the setting of AKI from tumor lysis syndrome, hyperuricemia is thought to cause kidney injury by intratubular obstruction and intrarenal inflammation by the precipitated crystals.[@bib20], [@bib21], [@bib22] Mechanisms beyond tubular obstruction are also potential contributors. In animal models, increased uric acid levels may lead to endothelial dysfunction,[@bib23], [@bib24] renin-angiotensin system activation,[@bib25] and oxidative stress.[@bib26]

Little is known about the role of uric acid in AKI outside of tumor lysis syndrome. We wanted to test the hypothesis that higher circulating uric acid levels are a risk factor for the development of AKI and its prognosis. To do so, we measured plasma uric acid in stored samples from 2 patient cohorts: (1) critically ill patients admitted to the ICU, and (2) patients with AKI-RRT enrolled into a randomized controlled trial of RRT intensity.

Methods {#sec1}
=======

Study Design and Population {#sec1.1}
---------------------------

We conducted a prospective study of the association between plasma uric acid levels and adverse clinical outcomes in 2 independent cohorts of critically ill patients. The first was a prospective observational cohort study and biorepository of patients admitted to the ICU at Brigham & Women's Hospital (BWH) between October 2008 and December 2016. This cohort is comprised of patients admitted to the medical and surgical ICUs at BWH and patients enrolled in the Registry of Critical Illness (ROCI) cohort study[@bib27] from the medical ICUs at BWH (collectively named ICU cohort). The second was the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network (ATN) Study, a multicenter randomized clinical trial of intensive versus less intensive RRT that enrolled critically ill patients between November 2003 and July 2007.[@bib28] All participants provided written informed consent for biomarker measurements. The study protocol was approved by the Partners Human Research Committee (the BWH Institutional Review Board: 2007P000894 and 2016P001542) and is in accordance with the principles of the Declaration of Helsinki.

Enrollment Criteria, Study Procedures, Selection of Time Points, and Data Collection {#sec1.2}
------------------------------------------------------------------------------------

Inclusion criteria for the ICU cohort were 18 years or older and admission to a medical or surgical ICU with blood samples available within 72 hours of arrival to the ICU. Exclusion criteria were: (1) current receipt of RRT, (2) anticipated ICU stay less than 48 hours, (3) admission to the ICU for a low-risk condition such as airway monitoring or serial neurologic checks, (4) pregnancy, or (5) enrollment in a conflicting research study. ICU patients were screened and enrolled intermittently through the study period. A total of 128 patients were eligible from the medical and surgical ICUs at BWH and 120 patients were eligible from the ROCI cohort. Because worsening kidney function can increase plasma uric acid levels, we adjudicated the medical record of each potentially eligible patient and excluded anyone with clinical evidence of AKI upon study enrollment based on serum creatinine (Scr) values. Eligible patients with an increasing Scr level before or upon study enrollment who met criteria for AKI were excluded. Patients with an elevated Scr value without prior values were excluded if they experienced improvement in Scr levels to a nadir that would have qualified them to meet criteria for AKI. We excluded 40 patients from the medical/surgical ICUs at the BWH and ROCI cohort due to clinical evidence of AKI upon study enrollment, which resulted in 208 patients in the ICU cohort. We obtained baseline demographic information, comorbid conditions, and severity of illness upon enrollment assessed using the Acute Physiology and Chronic Health Evaluation II (APACHE II) score.[@bib29] All patients were followed up until hospital discharge, death, or day 28 after enrollment, whichever occurred first.

The ATN Study was an interventional trial of higher versus lower intensity RRT that included critically ill patients diagnosed with AKI-RRT and with failure of at least 1 nonrenal organ system or sepsis. The study excluded patients with: (1) CKD (defined as premorbid Scr \> 2 mg/dL in men and \> 1.5 mg/dL in women), (2) AKI clinically believed to be due to a cause other than acute tubular necrosis, (3) prior kidney transplantation, and (4) comfort measures only status. Full inclusion and exclusion criteria for the ATN Study are described elsewhere.[@bib28] Among the 1,124 ATN Study participants, blood samples were collected in 817 participants. Because receipt of RRT would lower plasma uric acid levels, we excluded 561 participants who received some form of RRT before randomization. Of the remaining samples, 6 were deemed unsatisfactory for measurement, resulting in 250 individuals for inclusion in this study.

We obtained baseline characteristics including demographic information along with other pertinent clinical and laboratory data upon enrollment in the ATN Study. Severity of illness was obtained upon enrollment using APACHE II score and Sequential Organ Failure Assessment (SOFA) cardiovascular score. In the ATN Study, all participants were followed up daily until hospital discharge, death, or day 28 after randomization, whichever occurred first. Outcomes were ascertained daily during hospitalization and at day 60 and 1 year using telephone and/or mail follow-up.

Blood Sample Collection and Laboratory Assays {#sec1.3}
---------------------------------------------

In the ICU cohort, blood samples were collected in EDTA-containing vacutainers and were processed, aliquoted, and stored at −80°C within 4 hours of collection. In the ATN Study, blood samples were collected and immediately placed on ice and centrifuged at 4°C. They were separated into aliquots and stored frozen (−20°C) at the collection site until shipment. Batched samples were shipped on dry ice by commercial courier to the Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC) Core Laboratory at the Veteran's Affairs Boston Healthcare System. Samples were then stored at −80°C. Samples were shipped from MAVERIC on dry ice, thawed, and subaliquoted into 0.5-mL vials. Plasma uric acid measurements for the ICU cohort were performed at the laboratories of University of Washington (n = 115) and BWH (ROCI, n = 93). ATN Study samples were processed at the University of California San Diego. All uric acid assays were performed using the colorimetric peroxidase-coupled indirect equilibrium uricase method. The interassay coefficient of variation at each laboratory was \<10%.

Clinical Outcomes {#sec1.4}
-----------------

Authors A.S., R.P., D.E.L., and A.H. adjudicated outcomes by reviewing the medical record while still blinded to study measurements in the ICU cohort. The prespecified primary outcome was incident AKI (occurring after enrollment/arrival to the ICU). The secondary outcome was 90-day mortality. AKI was defined according to the Scr-based criteria established by the Kidney Disease: Improving Global Outcomes Work Group.[@bib30] Incident AKI was defined as a ≥ 0.3-mg/dL increase in enrollment Scr level over any 48-hour period during the first 7 days in the ICU or an increase in Scr level ≥ 1.5 times the enrollment Scr level within 7 days. AKI stage was defined as follows: stage 1, increase in Scr level of 1.5 to 1.9 times the enrollment Scr level or absolute increase ≥ 0.3 mg/dL; stage 2, increase in Scr level of 2.0 to 2.9 times the enrollment Scr level; and stage 3, increase in Scr level of ≥ 3.0 times enrollment, an absolute increase in Scr level ≥ 0.5 mg/dL to a level ≥ 4.0 mg/dL, or initiation of RRT. Urine output data were not available for all patients.

In the ATN Study cohort, the primary outcome was 60-day mortality. Secondary outcomes were 28-day mortality, duration of RRT (RRT-free days), and recovery of kidney function among survivors through day 28. To avoid the competing risk for death, RRT-free days were calculated as 28 minus the number of days requiring RRT assuming survival to 28 days. Any participant who died before 28 days was assigned a score of zero.[@bib31], [@bib32], [@bib33]

Statistical Analysis {#sec1.5}
--------------------

Descriptive statistics were summarized and presented as frequencies, mean ± standard deviation, or median with interquartile range (IQR). We assessed all variables for normality and log-transformed as appropriate. Plasma uric acid level was examined as a continuous variable (log base 2, so that interpretation would be per doubling of the exposure) and categorized as tertiles. We assessed the association between plasma uric acid levels and 2-group comparisons using Wilcoxon rank sum test and Kruskal-Wallis test for multiple group comparisons. We used Spearman correlation to assess the association between plasma uric acid levels and continuous variables. We used χ^2^ tests to compare plasma uric acid tertiles with categorical variables, and analysis of variance or Kruskal-Wallis tests for normally or non-normally distributed continuous variables, respectively. To assess for differences between the original ATN Study cohort and the subset of patients without RRT before randomization, we used *t* test for normal continuous data, Wilcoxon rank sum test for non-normal continuous data, and χ^2^ or Fisher exact test for categorical data. We evaluated predictors of plasma uric acid level in the ATN Study cohort using linear regression.

We fit multivariable logistic regression models to examine associations between plasma uric acid levels and the dichotomous outcomes of incident AKI, mortality, and renal recovery. Model results are reported as odds ratio (OR) with 95% confidence interval (CI). We used a multivariable negative binomial regression model for the outcome of RRT-free days. Model results are reported as relative number of RRT-free days with 95% CI. We assessed for confounding by iteratively generating increasingly adjusted models. All comparisons were 2 tailed, with *P* \< 0.05 considered significant. All statistical analyses were performed using SAS software (version 9.4; SAS Institute Inc.).

Results {#sec2}
=======

Characteristics of Study Participants {#sec2.1}
-------------------------------------

In the ICU cohort, mean age was 61.8 ± 15.3 years, 94 (45.2%) were women, and 177 (85.1%) were white. In the ATN Study, mean age was 62.0 ± 14.6 years, 77 (30.8%) were women, and 199 (79.6%) were white. The primary cause of AKI was multifactorial in 18 of 40 (45.0%) patients with AKI in the ICU cohort and in 135 (54.0%) participants in the ATN Study cohort. Additional baseline characteristics for the ICU and ATN Study cohorts are in [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}, respectively. [Tables S1](#appsec1){ref-type="sec"} and [S2](#appsec1){ref-type="sec"} show baseline characteristics for the ICU and ATN Study cohorts by their primary outcomes, respectively. Compared with characteristics of participants in the parent ATN Study not included in this study (n = 874), participants in the subcohort with plasma uric acid measurements were older, were more commonly white, required less mechanical ventilation, and had higher urine volume, blood urea nitrogen, and Scr values before RRT initiation ([Table S3](#appsec1){ref-type="sec"}).Table 1Baseline Characteristics of the ICU Cohort by Uric Acid TertilesCharacteristicAll Patients (n = 208)Tertile 1 (n = 67)Tertile 2 (n = 72)Tertile 3 (n = 69)Plasma uric acid,[a](#tbl1fna){ref-type="table-fn"} mg/dL4.7 \[3.6-6.4\] (1.5-20.3)1.5-3.94.0-5.85.9-20.3Demographics Female sex94 (45.2%)26 (38.8%)35 (48.6%)33 (47.8%) Age, y61.8 ± 15.357.6 ± 15.463.4 ± 15.364.2 ± 14.4 White177 (85.1%)61 (91.0%)61 (84.7%)55 (79.7%)Enrollment characteristics Scr, mg/dL0.8 \[0.6-1.0\]0.7 \[0.5-0.8\]0.8 \[0.6-1.0\]0.9 \[0.8-1.1\] eGFR, mL/min/1.73 m^2^91.1 ± 26.6102.2 ± 23.690.4 ± 26.181.1 ± 26.0 APACHE II score17 \[12-24\]16 \[11-22\]16 \[12-23\]18 \[13-27\] Sepsis113 (54.3%)42 (62.7%)30 (41.7%)41 (59.4%) AKI cause[b](#tbl1fnb){ref-type="table-fn"}40 (19.2%)9 (13.4%)12 (16.7%)19 (27.5%) Multifactorial18 (45.0%)2 (22.2%)6 (50.0%)10 (52.6%) Ischemic9 (22.5%)2 (22.2%)3 (25.0%)4 (21.0%) Prerenal6 (15.0%)3 (33.3%)2 (16.7%)1 (5.3%) Sepsis5 (12.5%)2 (22.2%)1 (8.3%)2 (10.5%) Other2 (5.0%)0 (0%)0 (0%)2 (10.5%)Comorbid conditions Active malignancy84 (40.4%)28 (41.8%)32 (44.4%)24 (34.8%) Chronic lung disease49 (23.6%)14 (20.9%)16 (22.2%)19 (27.5%) Diabetes mellitus44 (21.2%)8 (11.9%)10 (13.9%)26 (37.7%) Congestive heart failure12 (5.8%)2 (3.0%)2 (2.8%)8 (11.6%) Chronic liver disease10 (4.8%)4 (6.0%)3 (4.2%)3 (4.4%)ICU type Medical112 (53.9%)26 (38.8%)37 (51.4%)49 (71.0%) Surgical96 (46.1%)41 (61.2%)35 (48.6%)20 (29.0%)[^1][^2][^3][^4]Table 2Baseline Characteristics of ATN Study Participants by Uric Acid TertilesCharacteristicAll Participants (n = 250)Tertile 1 (n = 83)Tertile 2 (n = 83)Tertile 3 (n = 84)Plasma uric acid,[a](#tbl2fna){ref-type="table-fn"} mg/dL11.1 \[8.6-14.2\] (3.3-29.4)3.3-9.49.5-12.913.0-29.4Demographics Female sex77 (30.8%)31 (37.4%)25 (30.1%)21 (25.0%) Age, y62.0 ± 14.665.5 ± 13.160.5 ± 15.759.9 ± 14.5 White199 (79.6%)67 (80.7%)67 (80.7%)65 (77.4%)Premorbid characteristics Scr, mg/dL1.1 \[0.8-1.4\]1.0 \[0.8-1.3\]1.1 \[0.8-1.4\]1.1 \[0.9-1.4\] eGFR, mL/min/1.73 m^2^69.1 ± 32.872.1 ± 32.768.5 ± 33.766.8 ± 32.3 Weight, kg76.4 ± 15.673.1 ± 17.376.5 ± 13.479.5 ± 15.4Comorbid conditions[b](#tbl2fnb){ref-type="table-fn"} Cardiovascular disease82 (32.8%)30 (36.1%)21 (25.3%)31 (36.9%) Diabetes mellitus72 (28.8%)20 (24.1%)23 (27.7%)29 (34.5%) Malignancy50 (20.0%)15 (18.1%)17 (20.5%)18 (21.4%) Immunocompromised35 (14.0%)11 (13.3%)11 (13.3%)13 (15.5%) Cerebrovascular disease29 (11.6%)8 (9.6%)9 (10.8%)12 (14.3%) Chronic hypoxemia25 (10.0%)11 (13.3%)4 (4.8%)10 (11.9%)Enrollment characteristics  BUN before RRT, mg/dL69.5 ± 30.162.8 ± 31.367.1 ± 26.578.5 ± 30.3 Scr before RRT, mg/dL4.1 \[3.0-5.6\]3.6 \[2.7-4.7\]4.2 \[3.1-5.4\]4.7 \[3.7-6.3\] MAP, mm Hg76.0 ± 15.474.8 ± 15.377.7 ± 15.475.6 ± 15.5 Urine volume, mL/24 h195 \[72-545\]155 \[70-455\]255 \[107-532\]210 \[62-638\] Urine volume, mL/h10.9 \[4.2-26.0\]8.1 \[4.9-19.6\]12.2 \[5.3-26.3\]10.6 \[2.8-29.2\] Oliguria189 (75.6%)66 (79.5%)63 (75.9%)60 (71.4%) Mechanical ventilation189 (75.6%)65 (78.3%)62 (74.7%)62 (73.8%) APACHE II score26 \[21-31\]25 \[21-31\]27 \[22-32\]26 \[22-31\] SOFA cardiovascular score 0-2102 (40.8%)30 (36.1%)34 (41.0%)38 (45.2%) 3-4148 (59.2%)53 (63.9%)49 (59.0%)46 (54.8%) Treatment Intensive122 (48.8%)45 (54.2%)35 (42.2%)42 (50.0%) Less intensive128 (51.2%)38 (45.8%)48 (57.8%)42 (50.0%) ICU type Medical122 (48.8%)36 (43.4%)43 (51.8%)43 (51.2%) Surgical108 (43.2%)38 (45.8%)35 (42.2%)35 (41.7%) Other20 (8.0%)9 (10.8%)5 (6.0%)6 (7.1%) Postsurgical126 (50.4%)47 (56.6%)43 (51.8%)36 (42.9%) Cause of AKI[c](#tbl2fnc){ref-type="table-fn"} Ischemic198 (79.2%)66 (79.5%)66 (79.5%)66 (78.6%) Nephrotoxic48 (19.2%)16 (19.2%)15 (18.1%)17 (20.2%) Sepsis132 (52.8%)41 (49.4%)49 (59.0%)42 (50.0%) Multifactorial135 (54.0%)39 (47.0%)45 (54.2%)51 (60.7%)[^5][^6][^7][^8][^9]

Baseline Plasma Uric Acid Levels {#sec2.2}
--------------------------------

Median enrollment plasma uric acid level was 4.7 mg/dL with a range of 1.5 to 20.3 mg/dL in the ICU cohort. In the ATN Study, median plasma uric acid level before RRT was 11.1 mg/dL with a range of 3.3 to 29.4 mg/dL.

Factors Associated With Plasma Uric Acid Levels {#sec2.3}
-----------------------------------------------

There were no differences between plasma uric acid levels by sex, race, or ICU setting in the ICU or ATN Study cohorts. Plasma uric acid levels were higher in patients with a history of diabetes mellitus (6.4 \[IQR, 4.2-9.2\] vs 4.5 \[IQR, 3.5-6.0\] mg/dL; *P* \< 0.001) and congestive heart failure (8.0 \[IQR, 5.4-10.0\] vs 4.6 \[IQR, 3.6-6.3\] mg/dL; *P* = 0.007) in the ICU cohort. Plasma uric acid level had a positive correlation with APACHE II scores in the ICU cohort (*r*~*s*~ = 0.19; *P* = 0.007). In the ATN Study cohort, there were no significant differences in plasma uric acid levels by treatment arm, SOFA cardiovascular score, or presence of oliguria. Age was associated with plasma uric acid levels in the ICU cohort (*r*~*s*~ = 0.19; *P* = 0.006) and ATN Study participants (*r*~*s*~ = −0.13; *P =* 0.03). In the ICU cohort, plasma uric acid levels positively correlated with enrollment Scr levels (*r*~*s*~ = 0.36; *P* \< 0.001). In the ATN Study cohort, plasma uric acid levels had a positive correlation with enrollment blood urea nitrogen levels (*r*~*s*~ = 0.22; *P* \< 0.001), enrollment Scr levels (*r*~*s*~ = 0.29; *P* \< 0.001), and change in Scr level from admission to enrollment (*r*~*s*~ = 0.25; *P* \< 0.001). [Figure 1](#fig1){ref-type="fig"} demonstrates the correlation between enrollment Scr and plasma uric acid levels in both cohorts. [Table S4](#appsec1){ref-type="sec"} demonstrates unadjusted determinants of plasma uric acid levels in the ATN Study cohort.Figure 1Association between plasma uric acid and serum creatinine (SCr) levels. Scatterplots of enrollment plasma uric acid concentrations and their association with enrollment SCr levels in the intensive care unit (ICU) cohort (*r*~*s*~ = 0.36; *P \<* 0.001), and Acute Renal Failure Trial Network (ATN) Study cohort (*r*~*s*~ = 0.29; *P* \< 0.001).

Association of Plasma Uric Acid With Study Outcomes {#sec2.4}
---------------------------------------------------

In the ICU cohort, 40 (19.2%) patients developed AKI (52.5% had stage 2 or 3), and 52 (25.0%) patients reached the secondary outcome of 90-day mortality. Plasma uric acid levels were higher upon enrollment in patients who developed AKI compared with patients who did not (5.7 \[IQR, 4.1-7.8\] vs 4.6 \[IQR, 3.5-6.2\] mg/dL; *P* = 0.03; [Fig 2](#fig2){ref-type="fig"}). In the ATN Study cohort, 125 (50.0%) participants died at 60 days, 108 (43.2%) died at 28 days, and 65 (26.0%) who survived to day 28 experienced renal recovery. Mean number of RRT-free days was 6.7 ± 8.9. There were no differences in mortality or renal recovery by tertiles of plasma uric acid levels ([Fig 3](#fig3){ref-type="fig"}). [Tables 3](#tbl3){ref-type="table"} and [4](#tbl4){ref-type="table"} demonstrate unadjusted and adjusted associations of plasma uric acid levels with the renal and mortality outcomes, respectively.Figure 2Scatterplots of plasma uric acid levels in patients with and without acute kidney injury (AKI) in the intensive care unit (ICU) cohort. Plasma uric acid levels were higher in patients who developed AKI (5.7 \[IQR, 4.1-7.8\] mg/dL) compared with patients who did not (4.6 \[IQR, 3.5-6.2\] mg/dL; *P* = 0.03).Figure 3Association of plasma uric acid levels with mortality and renal recovery in the Acute Renal Failure Trial Network (ATN) Study cohort. Unadjusted association between plasma uric acid levels and adverse clinical outcomes. There were no differences in 60-day mortality, 28-day mortality, or alive with renal recovery through day 28 between the groups. Reference is tertile 1 and refers to plasma uric acid level range: 3.3 to 9.4 mg/dL; tertile 2: 9.4 to 12.9 mg/dL; tertile 3: 12.9 to 29.4 mg/dL. For 60-day mortality OR with (95% confidence interval \[CI\]), tertile 3: 0.93 (0.51-1.71), tertile 2: 0.65 (0.35-1.19); For 28-day mortality OR with (95% CI), tertile 3: 1.03 (0.56-1.89), tertile 2: 0.71 (0.38-1.31); For alive with renal recovery OR with (95% CI), tertile 3: 1.66 (0.72-3.86), tertile 2: 1.47 (0.65-3.32).Table 3Association of Uric Acid With Renal Outcomes in the ICU and ATN Study CohortsOutcomeNo. of EventsUnadjusted*P*Adjusted*P*ICU Incident AKI[a](#tbl3fna){ref-type="table-fn"}401.78 (1.03-3.05)0.041.50 (0.80-2.81)0.2ATN Study RRT-free days[b](#tbl3fnb){ref-type="table-fn"}---1.12 (0.70-1.79)0.71.07 (0.67-1.72)0.8 Renal recovery[b](#tbl3fnb){ref-type="table-fn"}651.40 (0.79-2.47)0.21.05 (0.54-2.04)0.9[^10][^11][^12][^13]Table 4Association of Uric Acid With Mortality in the ICU and ATN Study CohortsOutcomeEventsUnadjusted*P*Adjusted*P*ICU 90-d mortality[a](#tbl4fna){ref-type="table-fn"}521.16 (0.72-1.87)0.50.98 (0.57-1.67)0.9ATN Study 60-d mortality[b](#tbl4fnb){ref-type="table-fn"}1251.04 (0.69-1.57)0.91.15 (0.71-1.86)0.6 28-d mortality[b](#tbl4fnb){ref-type="table-fn"}1081.09 (0.72-1.65)0.71.16 (0.72-1.88)0.5[^14][^15][^16]

In the ICU cohort, higher plasma uric acid levels were associated with incident AKI (OR, 1.78; 95% CI, 1.03-3.05) but not 90-day mortality in unadjusted analyses (OR, 1.16; 95% CI, 0.72-1.87). After multivariable adjustment for age, diabetes mellitus, APACHE II score, and enrollment Scr level, plasma uric acid level was no longer associated with incident AKI (adjusted OR, 1.50; 95% CI, 0.80-2.81). Adjustment for enrollment Scr level alone was sufficient to render the association nonsignificant (adjusted OR, 1.49; 95% CI, 0.83-2.66).

In the ATN Study cohort, plasma uric acid levels were not associated with the primary outcome of 60-day mortality in unadjusted models. Adjustment for age, randomization arm (intensive vs less intensive RRT), urine output, enrollment blood urea nitrogen level, SOFA cardiovascular score, and APACHE II score did not change the association with 60-day mortality (adjusted OR, 1.15; 95% CI, 0.71-1.86). Similarly, there was no association between plasma uric acid levels and 28-day mortality (adjusted OR, 1.16; 95% CI, 0.72-1.88) or renal recovery (adjusted OR, 1.05; 95% CI, 0.54-2.04) among survivors through day 28 or change in RRT-free days (incident rate ratio, 1.07; 95% CI, 0.67-1.72) after multivariable adjustment. Substitution of estimated glomerular filtration rate (GFR) for Scr level in the multivariable adjustment did not fundamentally change results for either cohort.

Discussion {#sec3}
==========

In this study involving 2 cohorts of critically ill patients, we were unable to identify an association between uric acid level and subsequent risk for AKI or its complications. In the ICU cohort, higher plasma uric acid levels were associated with incident AKI in unadjusted models, but this effect was attenuated and no longer significant after multivariable adjustment. We found no statistically significant association between plasma uric acid levels upon admission to the ICU and 90-day mortality. In the ATN Study cohort, there was no statistically significant association between plasma uric acid levels and mortality, renal recovery, or duration of RRT in individuals with AKI-RRT.

Our results do not support the hypothesis that uric acid level predisposes to AKI in ICU patients or mortality in patients with established severe AKI. Preclinical evidence in favor of this hypothesis derives from both in vitro and in vivo studies, which established several potential mechanisms of kidney injury from uric acid, including afferent arteriole vasoconstriction,[@bib34], [@bib35] decreased renal blood flow due to endothelial dysfunction, oxidative stress,[@bib36], [@bib37], [@bib38] and augmentation of the inflammatory response.[@bib34] Our results also conflict with a number of published studies on the association between uric acid level and the development of AKI or risk for death.[@bib39] Higher uric acid levels have been reported to predict the risk for AKI in hospitalized patients[@bib40], [@bib41], [@bib42] and after cardiac surgery,[@bib16], [@bib17], [@bib18] with some reports of a J-shaped association showing higher risk at both very low and high uric acid levels.[@bib43] In the Atherosclerosis Risk in Communities Study, higher uric acid levels predicted risk for a hospital stay with AKI during a mean follow-up of 12 years, although results from Mendelian randomization analyses did not support a causal association.[@bib44] Prior retrospective studies in cardiac surgery have found increased risk for postoperative AKI in patients with higher preoperative uric acid levels.[@bib16], [@bib17], [@bib43] However, these prior studies in cardiac surgery adjust for kidney function as a dichotomous variable (estimated GFR \< 60 mL/min/1.73 m^2^), whereas adjustment as a continuous variable may address confounding by kidney function more appropriately. A recent prospective study in 247 patients undergoing cardiac surgery demonstrated that patients with preoperative uric acid levels ≥ 373 μmol/L (≥ 6.3 mg/dL) were at greater than 5-fold increased risk for the development of postoperative AKI even after adjustment for preoperative Scr level. However, this cohort had a relatively low event rate (12.1%) and also had limited power for the multivariable analysis.[@bib18] A prior prospective study of 144 critically ill patients suggested that higher plasma uric acid levels were associated with a secondary outcome of incident AKI by univariate analysis, but it is not clear whether individuals already had AKI upon ICU admission.[@bib42]

Our prospective study investigated whether higher plasma uric acid levels increased risk for the development of AKI and mortality in high-risk critically ill patients admitted to the ICU. We measured plasma uric acid within 72 hours of ICU admission in the ICU cohort and adjudicated the medical records to exclude patients with clinical evidence of AKI upon enrollment to reduce confounding by already worsening GFR in the setting of AKI. Despite reasonably well-preserved kidney function upon enrollment, the association of plasma uric acid level with incident AKI was still confounded by Scr level.

To our knowledge, this is the first study to evaluate the association of plasma uric acid level with mortality, renal recovery, and duration of RRT in patients with severe AKI requiring RRT. Few studies have evaluated the association of uric acid level with mortality in critically ill patients. In a study of 1,140 consecutive patients undergoing coronary artery bypass grafting, Hillis et al[@bib45] found 1.5-fold increased risk for all-cause mortality per 1.68-mg/dL increase in uric acid level over a median follow-up of 4.5 years. In the ATN Study cohort, plasma uric acid levels were significantly higher than the normal range. Despite the atypically high plasma uric acid levels and high event rates, we did not detect an association between plasma uric acid levels and the study outcomes even in unadjusted models. Severe AKI likely accounts for the high plasma uric acid levels, but a high inflammatory or hypercatabolic state in critically ill patients could also have contributed.

A recent scientific workshop reviewed the existing evidence for the association between uric acid levels and adverse outcomes in CKD and AKI. They suggested that there was insufficient evidence to recommend routine treatment of asymptomatic hyperuricemia in patients with hypertension, kidney disease, or diabetes mellitus to reduce the risk for AKI. The authors also called for more evidence from well-designed adequately powered clinical trials.[@bib46] Two small studies tested whether lowering plasma uric acid levels may be beneficial in reducing the risk for AKI after cardiac surgery and found no benefit when treated with preoperative allopurinol plus vitamin E or rasburicase (recombinant uricase), respectively.[@bib47], [@bib48]

We acknowledge that this study has several limitations. The single-center recruitment in the ICU cohort, heterogeneity of ICU patients, and lack of racial diversity in both cohorts limit the generalizability of the study results to all critically ill patients. We were unable to account for volume overload in our studies, which could dilute plasma uric acid levels. This may have been most pertinent in the ATN Study cohort because patients with AKI-RRT may develop volume overload with declining urine output. In addition, the modest sample size may have led to wide confidence intervals around the point estimates for the study outcomes, which did not reach significance. Therefore, we cannot exclude the possibility that we were unable to detect a potentially meaningful association between higher plasma uric acid levels and adverse clinical outcomes.

In summary, higher plasma uric acid levels measured in critically ill patients upon ICU admission and before RRT initiation were not observed to be statistically associated with the development of AKI or adverse clinical outcomes after AKI-RRT, respectively.
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[^1]: *Note:* Data presented as mean ± standard deviation or median \[IQR\] for continuous variables and frequencies for binary or categorical variables. eGFR was determined using the Chronic Kidney Disease Epidemiology Collaboration equation. Conversion factors for units: Scr in mg/dL to μmol/L, ×88.4; plasma uric acid in mg/dL to μmol/L, ×59.48.

[^2]: Abbreviations: AKI, acute kidney injury; APACHE, Acute Physiology and Chronic Health Evaluation; eGFR, estimated glomerular filtration rate; ICU, intensive care unit; IQR, interquartile range; KDIGO, Kidney Disease: Improving Global Outcomes; Scr, serum creatinine.

[^3]: Plasma uric acid presented as median \[IQR\] with range for all patients and range for each tertile.

[^4]: Percentages are per total KDIGO stage 1 or greater AKI in all patients and per tertile.

[^5]: *Note:* Data presented as mean ± standard deviation or median \[IQR\] for continuous variables and frequencies for binary or categorical variables. eGFR was determined using the Modification of Diet in Renal Disease Study equation. Conversion factors for units: Scr in mg/dL to μmol/L, ×88.4; plasma uric acid in mg/dL to μmol/L, ×59.48; BUN in mg/dL to mmol/L, ×0.357.

[^6]: Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; ATN, Acute Renal Failure Trial Network; AKI, acute kidney injury; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; ICU, intensive care unit; IQR, interquartile range; MAP, mean arterial pressure; RRT, renal replacement therapy; Scr, serum creatinine; SOFA, Sequential Organ Failure Assessment.

[^7]: Plasma uric acid presented as median \[IQR\] with range for all participants and range for each tertile.

[^8]: Cardiovascular disease includes participants with a history of myocardial infarction, angina, or congestive heart failure. Diabetes mellitus includes participants with a history of end-organ disease from diabetes, use of diabetic diet, or use of diabetic medications. Malignancy includes participants with a history of leukemia and tumors with or without metastasis. Immunocompromised includes participants with a history of human immunodeficiency virus infection, AIDS, or on immunosuppressive therapy. Cerebrovascular disease includes participants with a history of transient ischemic attack or stroke.

[^9]: Participants could have had more than 1 reason for AKI.

[^10]: *Note:* Plasma uric acid levels are log~2~ transformed. Measures of association presented as odds ratio with (95% CI) for dichotomous outcomes and relative number of RRT-free days with (95% CI).

[^11]: Abbreviations: AKI, acute kidney injury; APACHE, Acute Physiology and Chronic Health Evaluation; ATN, Acute Renal Failure Trial Network; CI, confidence interval; ICU, intensive care unit; RRT, renal replacement therapy.

[^12]: Adjusted for age, diabetes mellitus, APACHE II score, and enrollment serum creatinine level.

[^13]: Adjusted for age, randomization arm (high vs less intensity), natural log urine output, blood urea nitrogen level at enrollment, APACHE II score, and Sequential Organ Failure Assessment cardiovascular score.

[^14]: *Note:* Plasma uric acid levels are log~2~ transformed. Measures of association presented as odds ratio with (95% CI) for dichotomous outcomes. Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; ATN, Acute Renal Failure Trial Network; CI, confidence interval; ICU, intensive care unit; RRT, renal replacement therapy.

[^15]: Adjusted for age, diabetes mellitus, APACHE II score, and enrollment serum creatinine level.

[^16]: Adjusted for age, randomization arm (high vs less intensity), natural log urine output, blood urea nitrogen level at enrollment, APACHE II score, and Sequential Organ Failure Assessment cardiovascular score.
